MannKind Corporation (MNKD) vs Nektar Therapeutics (NKTR)
A side-by-side comparison of MannKind Corporation and Nektar Therapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MNKD
MannKind Corporation
$3.80HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
NKTR
Nektar Therapeutics
$40.12HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — MNKD vs NKTR
growth of $100 · dividends reinvested · last 10yMNKD +21.5% (+2.0%/yr)NKTR -83.4% (-16.4%/yr)MNKD compounded faster over this window
Log scale — wide-divergence pair
MNKD NKTR
MNKD vs NKTR: by the numbers
- •MNKD is the larger company ($1.21B vs $1.15B market cap).
- •Both run net losses; MNKD's is the smaller (-11.08% vs -287.84% net margin).
- •MNKD grew revenue faster over the past five years (39.51% vs -12.34% CAGR).
Metrics side by side
Valuation
| Metric | MNKD | NKTR |
|---|---|---|
| P/S ratio | 3.08 | 21.08 |
| P/B ratio | N/A | 1.27 |
| EV / EBITDA | 52.18 | N/A |
Profitability
| Metric | MNKD | NKTR |
|---|---|---|
| Gross margin | 75.69% | 99.36% |
| Operating margin | 11.12% | -240.38% |
| Net margin | -11.08% | -287.84% |
| ROE | N/A | -17.40% |
| ROIC | 1.32% | -12.53% |
Growth (annualized)
| Metric | MNKD | NKTR |
|---|---|---|
| Revenue CAGR (5Y) | 39.51% | -12.34% |
| Total return CAGR (5Y) | -4.18% | -30.33% |
Frequently asked
- Which has grown faster, MNKD or NKTR?
- Over the past five years, MNKD grew revenue faster — MNKD at a 39.51% CAGR versus NKTR at -12.34%.
- How have MNKD and NKTR total returns compared?
- Over the past 10 years, MNKD delivered 1.97% and NKTR delivered -16.49% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
MannKind ROENektar Therapeutics ROEMannKind operating marginNektar Therapeutics operating marginMannKind revenue growthNektar Therapeutics revenue growthMannKind free cash flowNektar Therapeutics free cash flow
MannKind & Nektar Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.